Table 2 Hypothetical immunotherapy protocol simulated
From: Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model
Protocol | DC | Inj. Interval | Number of | % of DCs | % of Decrease | Erad |
|---|---|---|---|---|---|---|
doses | (hours) | doses | ||||
2 | 102 | 168 | 3 | 50 | 12.61 | no |
3 | 103 | 168 | 3 | 50 | 19.92 | no |
4 | 104 | 168 | 3 | 50 | 20.79 | no |
5 | 105 | 168 | 3 | 50 | 20.95 | no |
6 | 106 | 168 | 3 | 50 | 68.65 | no |
7 | 107 | 168 | 3 | 50 | 88.69 | yes |
8 | 108 | 168 | 3 | 50 | 91.68 | yes |
9 | 109 | 168 | 3 | 50 | 91.68 | yes |
10 | 106 | 48 | 8 | 50 | 85.97 | yes |
11 | 106 | 72 | 5 | 50 | 83.70 | yes |
12 | 106 | 96 | 4 | 50 | 81.40 | yes |
13 | 106 | 120 | 3 | 50 | 76.05 | no |
14 | 106 | 144 | 3 | 50 | 76.72 | no |
15 | 106 | 192 | 2 | 50 | 37.12 | no |
16 | 106 | 216 | 2 | 50 | 33.11 | no |
17 | 106 | 168 | 3 | 100 | 80 | yes |
18 | 106 | 168 | 3 | 80 | 77.58 | yes |
19 | 106 | 168 | 3 | 60 | 73.05 | no |
20 | 106 | 168 | 3 | 40 | 60.33 | no |
21 | 106 | 168 | 3 | 20 | 22.16 | no |